The phase III BELLINI trial demonstrated translocation (11;14) and high BCL2 gene expression are predictive of response to treatment with the addition of venetoclax to bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma, according to the findings presented at the 2019 ASH Annual Meeting.
Medical specialists analyze the case of a 58-year-old man presenting to the emergency room with hematuria and abdominal pain, while considering the most recent clinical…
A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear…
Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear…
The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to…
As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and population at large to…
Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and…
The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of…
The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung cancer, regardless of PD-L1 expression.
